#TcellEngager
T-Therapeutics completed a Series B round raising $133 million to advance its bispecific antibody programs TTX-008 and TTX-018. The funding supports proof-of-concept data generation for cancer and autoimmune treatments.

#TCellEngager #BispecificAntibody #ClinicalDevelopment
T-Therapeutics raises $133 million
Source: BioPharma Dive
realfeedapp.com
November 5, 2026 at 3:22 PM
#Novartis has added a #Tcellengager (TCE) developed by China's #AbogenBiosciences for #autoimmunedisorders in a deal that could be worth over $7.5 billion.

buff.ly/XBf4uCh
Novartis taps China's Abogen for autoimmunity TCE
Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
buff.ly
October 2, 2026 at 2:45 PM
#GSK has continued its drive to bulk up its #pipeline, taking global rights to a #Tcellengager (TCE) for #multiplemyeloma, developed by China's #ChimagenBiosciences, for up to $750 million.

buff.ly/K4aTZIu
GSK wagers $750m on Chimagen multiple myeloma therapy
GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.
pharmaphorum.com
September 15, 2026 at 2:01 PM
#AbbVie has reported positive results with #Tcellengager etentamig in relapsed or refractory #multiplemyeloma, a key programme in the company's expansion into the #oncology sector.

pharmaphorum.com/news/abbvies...
AbbVie's cancer TCE etentamig hits the mark in myeloma
AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?
pharmaphorum.com
September 4, 2026 at 9:59 AM
#CytospireTherapeutics was in the spotlight this morning after announcing an oversubscribed #SeriesA to fund a new form of #Tcellengager (TCE) that it thinks can improve on the efficacy and safety of current therapies.

pharmaphorum.com/news/uks-cyt...
UK's Cytospire draws in $83m for new T-cell engager platform
Cytospire was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of T-cell engager (TCE) for cancer.
pharmaphorum.com
May 5, 2026 at 11:27 AM
Antibody Therapeutics (IF=4.5, Oxford University Press) ⚡ Research Highlight - "Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers"
doi.org/10.1093/abt/...
#antibody #antibodydrugconjugate #tcellengager #gammadeltatcells #immunotherapy
Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers
Statement of Significance We developed two novel complementary therapeutic modalities targeting an emerging gastrointestinal tumor-associated antigen, CDH1
doi.org
August 6, 2026 at 9:49 PM
New Article Alert from Antibody Therapeutics(IF=4.5, Oxford University Press)
🔥🔥🔥Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy
academic.oup.com/abt/advance-...
#Bispecific #Multispecific #TcellEngager
January 19, 2026 at 4:20 PM
🧬 BREAKTHROUGH: Novel bispecific T cell engager IMA401 targeting MAGE-A4/MAGE-A8 shows encouraging safety & efficacy signals in phase 1a trial…

#Bispecificantibodies #Cancerimmunotherapy #MAGEA4 #Phase1trial #Tcellengager

#Bispecificantibodies #Cancerimmunotherapy #MAGEA4 #Phase1trial #Tcelleng…
New Cancer Therapy Shows Promise in Phase 1 Trial
🧬 BREAKTHROUGH: Novel bispecific T cell engager IMA401 targeting MAGE-A4/MAGE-A8 shows encouraging safety & efficacy signals in phase 1a trial… #Bispecificantibodies #Cancerimmunotherapy #MAGEA4 #Phase1trial #Tcellengager
news.gmj.ge
June 8, 2026 at 12:18 PM
A "new contender" (and a client) enters the #TcellEngager and #Bispecific #ADC arena with a novel, conditionally activated TCE strategy called #BiTAC. Interested to hear people’s thoughts on this one...

#AACR2026 #CancerResearch #Immunotherapy
At this year's @theaacr.bsky.social AACR Annual Meeting 2026, we will present preclinical data on two of our pipeline programs and share insights on the capabilities of our novel #BiTAC technology platform.

#Oncology #ADCs #TCEs #AACR26
April 13, 2026 at 3:54 PM